AN2 Therapeutics, Inc.
ANTX • NASDAQ
AN2 Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Eric E. Easom, with a market cap of $131.5M.
CEOEric E. Easom
Next Earnings
Upcoming earnings announcement for AN2 Therapeutics, Inc.
Date
Tuesday, May 12, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.23
Earnings History
Past 12 earnings reports for AN2 Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 17, 2026 | Q4 2025 | -$0.29Est: -$0.24 | -20.8% | - | — | — |
| Nov 12, 2025 | Q3 2025 | -$0.31Est: -$0.22 | -40.9% | - | — |  10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.21Est: -$0.31 | +32.3% | - | — | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.35Est: -$0.25 | -40.0% | - | — | 10-Q |
| Mar 25, 2025 | Q4 2024 | -$0.25Est: -$0.26 | +3.8% | - | — | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.43Est: -$0.54 | +20.4% | - | — | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.48Est: -$0.59 | +18.6% | - | — | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.56Est: -$0.62 | +9.7% | - | — | 10-Q |
| Mar 28, 2024 | Q4 2023 | -$0.57Est: -$0.76 | +25.0% | - | — | 10-K/A |
| Nov 9, 2023 | Q3 2023 | -$0.65Est: -$0.70 | +7.1% | - | — | — |
| Aug 10, 2023 | Q2 2023 | -$0.81Est: -$0.85 | +4.7% | - | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.79Est: -$0.68 | -16.2% | - | — | — |